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An Evaluation of Service Provision and Novel Strength Assessment on 1 
Patient Outcomes in a UK based Pulmonary Rehabilitation Setting 2 
 3 
This study’s purpose was to (i) assess the impact of a 7-week Pulmonary 4 
Rehabilitation (PR) programme upon patient outcomes; incremental shuttle walk 5 
test (ISWT), COPD assessment tool (CAT), Clinical COPD Questionnaire (CCQ) 6 
and the Hospital Anxiety and Depression Scale (HADS); (ii) assess the impact of 7 
COPD severity on ISWT and psychological functioning and quality of life 8 
measures following PR; (iii) assess the feasibility of incorporating individually 9 
prescribed one repetition maximum (1RM) training loads into the existing 10 
strength training programme.  11 
Patients were people with COPD enrolled onto one of three versions (locations 12 
A, B & C) of a 7-week PR programme, which consisted of group exercise 13 
sessions and a social plus education element. Two locations incorporated 14 
individually prescribed training loads. 15 
 16 
Minimal Clinically Important Changes (MCIC) are reported for the ISWT across 17 
all locations. Statistically significant changes in both CAT and the CCQ were 18 
found, with MCIC’s evident for CAT score overall and individually at location B. 19 
MCIC’s were not found for the CCQ. No statistically significant or MCIC were 20 
evident for the HADS.  MCIC’s were present only in patients with mild to 21 
moderate severity for the ISWT. For the CAT, moderate, severe and very severe 22 
patients with COPD experienced MCIC’s. MCIC’s and statistically significant 23 
increases in 1RM strength were seen at both locations.  24 
These findings evidence an effective PR service. Basic strength exercise 25 
programming and assessment are feasible and should be implemented in PR 26 
services to maximize patient outcomes. 27 
 28 








Chronic obstructive pulmonary disease (COPD) is recognised as a leading 5 
respiratory disease with three million deaths worldwide each year with increasing 6 
mortalities [1]. Pulmonary Rehabilitation (PR), one of the established COPD treatment 7 
strategies is considered critical for individuals living with chronic respiratory diseases. 8 
It typically includes exercise programs alongside educational elements [2,3]. PR has 9 
been shown to be successful in improving exercise tolerance and health-related quality 10 
of life, and has been shown to reduce hospital admissions rates in patients with COPD 11 
[4,5]. Exercise training is reported as the cornerstone of PR programs [6] and 12 
incorporates many types of exercise including aerobic endurance, high intensity interval 13 
training, whole body and localized resistance training [7-9]. Patients with COPD  are 14 
commonly associated with muscular atrophy, peripheral muscle weakness, low levels of 15 
activity and comorbidities indicated with inactivity [10]. Studies have shown that 16 
exercise interventions [7] and in particular resistance exercise, including free weights 17 
and elastic bands [11-13] can improve not only muscle strength and exercise capacity, 18 
but also quality of life in patients with COPD [14,15].  Resistance exercise is therefore 19 
integral to PR programs [16].  20 
Although shown to be effective PR programs are typified by patient non-21 
completion, low exercise adherence and poor continuance following discharge [17]. 22 
Resistance training and exercise prescription in healthy populations are founded upon 23 
key programming variables: (1) repetition maximum (RM); (2) number of sets; (3) 24 
choice of exercise; (4) order of exercises; and (5) rest periods and are necessary for safe 25 




programme outcomes should be incorporated wherever possible [19]. There is a 1 
necessity to identify peripheral muscle weakness prior to PR to prescribe appropriate 2 
resistance loads [20], particularly as strength has marked decrements in patients with 3 
COPD, especially in severe COPD [21]. Despite knowledge of these fundamental 4 
principles, only 27% of current UK PR services implement baseline strength training 5 
assessment, with no indication of post training assessment or individual load 6 
prescription [22]. Further, the variable application of strength assessment and 7 
subsequent prescription indicates the provision of ineffective strength training by 8 
clinical experts [23]. The incorporation of pre/post assessment and progressive, 9 
individualized strength training in PR settings will aid PR services [24]. This could lead 10 
to improved patient outcomes and even promote future exercise adherence. Negative 11 
outcomes regarding program adherence, program continuance and the long term 12 
benefits of PR programs have been documented [22,25]. Further to this patients have 13 
cited a need for programme value and exercise acceptability [26]. Therefore provision 14 
of effective, acceptable patient valued programs, i.e. improved exercise-associated 15 
confidence and competence, is key. Strength can be measured in patients using a diverse 16 
range of methods; however the application of a one repetition maximum (1RM) 17 
estimation formula remains a simplistic measurement to implement [20,27,28]. Since 18 
individuals living with COPD experience ventilatory limitations during whole-body 19 
endurance training [29], designing exercises which isolate specific muscle groups 20 
diminishes the ventilatory load and increases the effectiveness of PR. The exercise 21 
program and assessment in the current study focusses on isolated upper and lower limb 22 
movements, as quadriceps and biceps have been suggested as the muscles group most 23 
affected by the patients’ low physical activity levels [7,30]. Understanding which 24 




baseline characteristics such as severity of lung function, skeletal muscle dysfunction 1 
and inspiratory muscle strength have produced conflicting findings with regard to 2 
predicting patient outcomes and PR effectiveness [32-35].  3 
The primary purpose(s) of this service evaluation, in a cohort of patients with 4 
COPD, using only the usual parameters obtained as part of an ongoing PR programme 5 
were to: (i) assess the impact of a 7-week PR programme upon patient outcome 6 
measures; incremental shuttle walk test (ISWT) distance, and psychological functioning 7 
and quality of life measures including the COPD assessment tool (CAT), the Clinical 8 
COPD Questionnaire (CCQ) and the Hospital Anxiety and Depression Scale (HADS) 9 
respectively; (ii) assess the impact of COPD severity on ISWT, psychological 10 
functioning and quality of life measures; and (iii) assess the feasibility of incorporating 11 
individually prescribed one repetition maximum (1RM) training loads into the existing 12 
strength training programme.  A further aim of this study is to contribute to current 13 
understanding about factors influence adherence to PR programmes of this kind. The 14 
primary hypothesis was that the 7 week PR programme would lead to significant 15 
improvements in; ISWT distance, 1RM and all psychological functioning and quality of 16 
life measures. The secondary hypothesis was that improvements in ISWT distance, 17 
psychological functioning and quality of life outcomes would differ in patient groups.  18 
 19 
Materials and methods 20 
Patients and design 21 
This between-within design study examined a cohort of patients with COPD, using 22 
only outcome measures obtained as a matter of routine practice at the start and end of a 23 




versions of a 7-week PR programme between September 2016 and November 2017 1 
(patients attended the programme version closest to their home address). Patient 2 
diagnosis and classification were based upon Global Initiative for Chronic Obstructive 3 
Lung Disease (GOLD) 2017 guidelines [36]. Patients were diagnosed upon spirometry 4 
(the presence of a post-bronchodilator FEV1/FVC < 0.70) and symptoms indicating 5 
COPD i.e. dyspnea, chronic cough or sputum production. Patients were a real world 6 
cohort with a range of comorbidities and accompanying pharmacological treatments. 7 
 8 
Programme versions 9 
A local healthcare provider ran three near identical 7-week PR programmes in 10 
different geographical locations. In accordance with BTS Guidelines [37], these 11 
consisted of group exercise sessions (14 hours) and a ‘social plus education’ element 12 
(14 hours; occurring after each exercise session where patients socialised and talked 13 
with invited experts on specific topics e.g. inhaler use).  14 
The group exercise component of the programme comprised a twice-weekly, 15 
one hour circuit-style exercise class, whereby patients completed a 10 minute warm up, 16 
followed by a 48 minute circuit of 12 exercise ‘stations’, followed by a short active cool 17 
down. Each exercise within the circuit had a duration of 2 minutes, whereby patients 18 
completed as many repetitions of the exercise as they were able to. A 2-minute rest 19 
period followed each exercise, with continuation of exercise during this rest period 20 
when patients felt able and motivated to do so. 21 
Although patients started at different points within the circuit, the order of 22 
stations was: walking; wall push-off; heel raises; cycling or step-ups; side arm raises; 23 
squats; bicep curls (programme versions A and C) / leg extensions (programme version 24 




of exercise intensity and exercise progression utilised the Borg scale as per American 1 
College of Sports Medicine (ACSM) guidelines [38,39]. 2 
The only difference between programmes (A, B, C) was one specific exercise 3 
completed within the group exercise sessions. Patients attending version A completed 4 
bicep curls, whereby each participant was individually prescribed an optimal training 5 
load. At the first PR session the patients completed 2 sets of 6 repetitions at 50% 1RM 6 
as per American Thoracic Society (ATS) guidelines [38,39]. Patients were then 7 
encouraged to increase repetitions by 1 at the next exercise session until a load 8 
difficulty of 10 repetitions per set was completed. The weight was then increased by 9 
0.5-1kg and repetitions reduced back to 2 sets of 6 [40]. Patients attending version B 10 
completed leg extension exercise instead of bicep curls, again following an 11 
individualised prescribed and progressive training load. Patients attending version C 12 
completed bicep curls at self-selected training loads, whereby they were free to choose 13 
any resistance theraband (yellow, red or blue), number of reps and sets, within each 14 
session.  15 
Predicted 1RM calculation 16 
At locations A (biceps) and B (quadriceps), Epley’s prediction protocol and 17 
equation was used to calculate patient 1RM in order to reduce the risk of injury or 18 
fatigue to the patient [41,42]. The health professional initially estimated a suitable 19 
weight for the patient to lift, aiming for 10% of the patient’s body weight and taking 20 
their overall condition into consideration. The exercise technique was demonstrated and 21 
the patient was asked to lift the selected weight as many times as possible. If the patient 22 
was able to lift the allocated weight more than 10 times, a heavier weight was then 23 






Both at the start and the end of the 7-week programme, a health professional 2 
collected data as described below. The outcome measures used within the analyses were 3 
routinely collected by the service. Questionnaires were completed in a random order, 4 
either before or after the walking test. Patients completed their own questionnaires, 5 
unless in the case of literacy or sight issues, whereby a member of staff would read the 6 
questions to the patient. Predicted 1RM (as described above) was additionally measured 7 
at these time points. 8 
The Incremental Shuttle Walk test (ISWT) 9 
The ISWT is a validated walking test and is sensitive to changes after PR [43,44]. 10 
The test is a maximal externally paced incremental exercise test and assesses exercise 11 
capacity. Using instructions standardised from an audio recording, patients walk back 12 
and forth between markers paced 10-metres apart, whereby the walking speed is 13 
increased slightly each minute. The ISWT score is a record of how far the patient has 14 
walked in metres before a participant could no longer complete a shuttle in the time 15 
allowed (i.e. more than 0.5 m away from the cone when the beep sounded). Higher 16 
scores indicate greater functional capacity, and the minimal clinically important change 17 
(MCIC) for the ISWT is between 35.0 and 36.1 metres [45]. A practice test was 18 
conducted as recommended [44]. Patients then rested for 30 minutes before repeating 19 
the test.  20 
COPD Assessment Tool (CAT) 21 
The CAT is a validated patient-completed questionnaire that assesses the impact of 22 
COPD on an individual’s health status [46]. Previous PR research has used the CAT to 23 




whereby higher scores indicate poorer health status, and the MCIC in the CAT is 2 1 
points [47]. 2 
The Clinical COPD Questionnaire (CCQ)  3 
The CCQ is a self-administered10-item questionnaire that measures quality of life in 4 
patients with COPD. It is designed to evaluate treatment whilst incorporating both the 5 
clinician’s and patient’s goals [48]. Higher scores indicate worse quality of life, and a 6 
score decrease of 0.4 or more is considered to be clinically significant [49].  7 
The Hospital Anxiety and Depression Scale (HADS) 8 
The HADS is a self-administered 14 item questionnaire of which, 7 items assess 9 
anxiety and 7 assess depression [50]. The HADS is used to assess anxiety and 10 
depression in clinical settings and is recommended for use in PR [41]. Higher scores 11 
indicate more severe anxiety or depression, with scores higher than 10 indicating 12 
probable presence of disorder [51]. The MCIC in each of the HAD subscales is 1.7 13 
points [52]. 14 
 15 
Statistical analyses 16 
Data from all patients was included for analyses of adherence to the programmes. A 17 
series of Mann-Whitney U tests (as data was non-normally distributed; for interval scale 18 
variables at the start of the programmes: Age; CAT; CCQ; ISWT; HADS Anxiety; 19 
HADS Depression) and chi-square tests (for nominal variables: Gender; COPD severity 20 
status; Smoking status; Programme Location) were used to examine potential 21 
differences in baseline characteristics between adherers (patients who attended at least 22 
75% of the exercise component of the programmes) and non-adherers. To additionally 23 




a series of binary logistic regressions were performed (a series of single regressions was 1 
used in order to avoid potential suppressor effects within a single, multiple logistic 2 
regression model). 3 
Only data from adherers was included for analysis of outcomes. For each 4 
variable other than 1RM (ISWT, CAT, CCQ & HADS), changes from start to end of the 5 
programme across each location were first assessed though interpreting magnitudes of 6 
change as indicated by descriptive statistics, in relation to MCIC values. 7 
Presence of statistically significant effects of time and of time-by-location 8 
interactions were then tested for using a series of two-way mixed (between, within) 9 
ANOVA tests.  10 
The factor of ‘programme location’ was then collapsed and data was grouped by 11 
severity status of COPD. First, magnitudes of change (as indicated by descriptive 12 
statistics) were assessed in relation to MCIC values. Presence of statistically significant 13 
effects of COPD severity categories were then tested for via a series of one-way 14 
ANCOVAs on end of programme values, whereby start values were included as the 15 
covariates.  16 
As most of the psychological and quality of life measures (ISWT, CAT, CCQ & 17 
HADS) were not normally distributed across all levels, median values are given in 18 
Tables 2 and 3, in addition to mean values. However, parametric tests were used to 19 
examine the data, as ANOVA tests are relatively robust to violations of the assumption 20 
of normal distributions, particularly with sample sizes over 20 [53], and because there 21 
are not adequate non-parametric equivalent tests to ANCOVA. 22 
For the measure of 1RM, descriptive values were assessed in relation to MCIC 23 
values, and Wilcoxon ranked sign tests were used to assess the statistical significance of 24 




(quadriceps). MCIC were calculated using an distribution based approach according to 1 
Vaidya et al. [54]. The calculated 1RM MCICs within the current study were 0.324kg 2 
for biceps (location A) and 2.47kg for quadriceps (location B). 3 
An alpha level of 0.05 was used to indicate statistical significance. As not all 4 
patients completed all measures at each time-point, sample size analysed varies between 5 
measures.  6 
All analyses were performed using SPSS (Version 25.0 Armonk, NY: 7 
IBM CORP). 8 
 9 
Results  10 
Patients 11 
Data was recorded for 322 patients. Table 1 presents mean and frequency descriptive 12 
statistics for age, sex and severity of COPD by programme version (detail about the 13 
programmes is given in ‘The Programmes’ section). Severity of COPD condition was 14 
only recorded for 106 patients. The proportion of patients of differing COPD severity 15 
did not significantly differ between locations (Χ2 (6) = 8.90, p = 0.18).  16 
 17 
Table 1. HERE 18 
 19 
Adherence 20 
233 patients (72%) successfully adhered to the programmes (79% adherence at 21 
location A; 79% at location B; 62% at location C). At the start of the programmes there 22 
were small but statistically significant differences between adherers and non-adherers 23 




whereby 81% of non-smokers adhered, compared to only 66% of smokers and 59% of 1 
ex-smokers; and programme location status as reported on above (X2 (2) = 10.818, p= 2 
0.004, Cramer’s V= 0.18). There were no statistically significant differences for the 3 
variables of Age, CAT, CCQ, ISWT,  HADS Anxiety, HADS Depression, COPD status 4 
and gender (p> 0.05). 5 
Smoking status predicted 2.9% (Cox & Snell R2= 0.029) – 4.1% (Nagelkerke R2= 6 
0.041) of adherence likelihood, and this was statistically significant (X2 (2, n= 262) = 7 
7.642, Wald = 7.255, p= 0.027). Smokers were only 47% (95% CI for Exp. B [0.259, 8 
0.859]) as likely, and ex-smokers were only 34% (95% CI or Exp. B [0.117, 1.016]) as 9 
likely as non-smokers to adhere to the programme. 10 
Programme location also predicted 3.3% – 4.7% of adherence likelihood to a 11 
statistically significant extent (X2 (2, n= 326) = 10.663, Wald = 10.579, p= 0.005). On 12 
average, patients at Locations A (95% CI for Exp. B [1.26, 4.24]) and B (95% CI [1.24, 13 
4.12]) were twice as likely to adhere compared to patients at location C. 14 
Finally, HADS Anxiety at the start of the programme predicted 1.9% – 4.7% of 15 
adherence likelihood to a statistically significant extent (X2 (1, n= 225) = 4.317, Wald = 16 
4.492, p= 0.038). For each one-point increase in HADS Anxiety score was associated 17 
with a 12% decreased likelihood (95% CI for Exp. B [0.779, 0.99]) of adhering to the 18 
programme. 19 
No other variables (age, COPD status, gender, and each of CAT, CCQ, HADS 20 
depression and ISWT as measured at the start of the programme) predicted adherence to 21 






Both biceps (location A) and quadriceps (location B) surpassed the calculated 3 
MCICs. Wilcoxon ranked sign tests found that at each of location A (Z= -4.540, 4 
p<0.001, n= 47) and location B (Z= -4.245, p<0.001, n= 42) there were statistically 5 
significant trends of increased Epley’s 1RM scores from the start to end of PR. 6 
ISWT, quality of life and psychological functioning measures 7 
Inspection of the mean values shown in Table 2 indicates that the changes in ISWT 8 
were clinically important across all locations. A nearly clinically important change in 9 
CAT was found across the total sample (only 0.1 short of the critical change value), 10 
with a clinically important change reported at programme location B. Overall reported 11 
changes in CCQ were 75% of the magnitude considered clinically important. Changes 12 
in HADS anxiety and depression scores were negligible, with little variation between 13 
programmes. 14 
A series of mixed two-way ANOVAs found statistically significant 15 
improvements from start to end of the PR programmes for the measures of ISWT 16 
(F1,168= 81.93, p< 0.001, η
2 = 0.33), CCQ (F1,198= 6.80, p= 0.01, η
2 = 0.03), CAT (F1,203= 17 
20.55, p< 0.001, η2 = 0.09). There were no statistically significant effects for time for 18 
HADS anxiety and depression, (p> 0.05). There were no statistically significant time by 19 
location interactions effects across the outcome measures (p> 0.05). 20 
COPD severity status 21 
Inspection of the mean change values in Table 3 indicates that clinically important 22 
improvements were seen for the mild and moderate severity patients for the ISWT. For 23 




improvements. For CCQ, HADS anxiety and HADS depression none of the COPD 1 
categories showed clinically important mean improvement. 2 
A series of one-way ANCOVAs found that after controlling for start of the 3 
programme scores, there was not a statistically significant effect for starting COPD 4 
severity status on end of programme values for ISWT (p= 0.061), CAT (p= 0.263), 5 
CCQ (p= 0.651), HADS anxiety (p= 0.938) or HADS depression (p= 0.692). 6 
 7 
Table 2 HERE 8 
Table 3 HERE 9 
 10 
Discussion 11 
Overall the findings from the current study indicate the provision of an effective PR 12 
service as evidenced by statistical and clinically important changes in both incremental 13 
shuttle walk test (ISWT) distance and quality of life outcomes. Further the feasibility of 14 
incorporating individualised load prescription based off a 1RM assessment was possible 15 
and effective.  16 
Contextually the findings from this service evaluation are consistent with a recent 17 
national audit within the UK [22]; that PR programmes are effective at improving 18 
outcomes measures such as the ISWT. Statistically significant and Minimally Clinically 19 
Important Changes (MCIC) are reported for the incremental shuttle walk test (ISWT) 20 
across all locations. These findings are similar to those seen following similar length PR 21 
programmes for the ISWT and provide evidence for an effective PR service [45,55].  22 
Secondary findings show that MCIC’s were present only in patients with mild to 23 
moderate severity for the ISWT. It is perhaps intuitive that mild to moderate COPD 24 




capacity levels decline with severity of disease [56] and in part may be related to a 1 
reduced capacity for improvement within the severe to very severe patient categories. 2 
However, Altenburg and colleagues demonstrated a better response in exercise capacity 3 
in more severe patients following an intensity tailored PR programme [32], suggesting 4 
that with correct exercise prescription, improvements can be experienced by all. 5 
 6 
Evaluation of psychological functioning, health status, quality of life and depressive 7 
symptoms is common place within National Health Service (NHS) practice and 8 
important to establish the benefit or treatment and practice upon a patient. For the CAT, 9 
moderate, severe and very severe patients with COPD experienced clinically important 10 
improvements. MCIC’s were not evident for the CCQ and HADS anxiety and 11 
depression scores for any COPD classification. The CAT and CCQ are tools that 12 
evaluate health status and quality of life respectively, and positive changes would be 13 
expected following an improvement in exercise capacity, which is consistent with the 14 
findings of others [55,57-59].  Higher rates of depression and anxiety have been found 15 
in patients with COPD compared to the normal population and so it has been postulated 16 
that PR may improve anxiety and depression [60,61]. This service evaluation saw no 17 
changes within HADS score, which is in contrast to other studies, which have evidenced 18 
improvements [61-63], albeit differences between studies including; in-patient 19 
rehabilitation, length of rehabilitation and specific tool to measure the construct may 20 
account for this. The simplest explanation however, may be, that patients initially 21 
reported low levels of anxiety and depression, nearly as much as half as those reported 22 
by Garuit et al. [61]. Given the ‘ceiling’ effect for initial values, effective PR service 23 
and opportunity to socialize with other patients, improved depressive scores were 24 




(PROMs) be used as an alternative, or potentially measures to assess exercise 1 
enjoyment or exercise self-efficacy - both predictors of continuance [64]. This may hold 2 
more value for behavior change, programme adherence and exercise / activity 3 
continuance. Similarly, the use of focus groups or individual questioning of existing 4 
patient may better inform effective PROMs use and should form part of a patient 5 
programme exit process. 6 
Tertiary findings were that across both implemented locations (A: biceps and B: 7 
quadriceps), there were clinically important and statistically significant increases in one 8 
repetition maximum (1RM) strength. Increases at both locations was not unexpected as 9 
theraband (elastic) resistance training has previously been shown to be as effective as 10 
free weights for improving strength in various populations including patients with 11 
COPD [12,65]. 12 
There is a growing body of evidence to support the application of strength 13 
training and its effectiveness in PR programs [7,11,13]. Here we have shown that it is 14 
possible to use a simplistic clinically appropriate methodology [66-68] to establish 1RM 15 
and incorporate this within a PR programme. This in itself holds value for the service 16 
and others that wish to implement such an approach. This small ‘pilot’ application can 17 
be used as the basis for both structured upper and lower limb strength training programs 18 
that would lead to improved isolated limb strength. The use of basic programming 19 
principals [18] will impact upon service outcome measures (strength and functionality), 20 
but could also help combat the major issue of programme continuance [17]. Based on 21 
the findings of Cook et al. that patients need to see the value within a programme to 22 
‘buy in’ and adhere [26], value will arguably most easily be seen through personally 23 
experienced improvement.  Stone and colleagues also identified that any patient who 24 




three times likely to complete their PR programme [69]. Additionally strength training 1 
has been shown to be an effective therapy for depressive symptoms [70], which may 2 
hold importance due to the common relationship between depression and COPD 3 
[71,72]. In order to fully quantify the benefits of individually prescribed training loads 4 
(a limitation here) robust, patient preference-based MCIC’s need to be established for 5 
upper and lower limb strength in COPD. As such we calculated 1RM MCIC’s using a 6 
distribution based approach in order to facilitate this for future clinicians and 7 
researchers. In context, the improvements in 1RM leg strength seen in the current study 8 
are comparable to those seen by Daabis et al. [59], who utilised an 8 week 3x per week 9 
combined resistance and endurance training programme. It would have been valuable to 10 
have also evaluated the impact of COPD severity upon strength improvement, as this 11 
could potentially enable a much needed targeted approach for PR services [31]. This 12 
was not however possible due to incomplete data collection and is a requirement for 13 
further assessment and evaluation.  14 
Although only predicting small percentages of adherence likelihood, the 15 
findings that HADS Anxiety, smoking status and programme location influenced the 16 
likelihood of adherence within the current study alludes to the potential importance of 17 
targeting future interventions more efficiently, so to reduce dropout rates and wasted 18 
resource. For example, perhaps amendments can be made to align some programmes 19 
more closely with the needs of patients who experience greater anxiety.  The findings 20 
that smoking status [73-76] and anxiety [75,77] influenced adherence are consistent 21 
with many other studies. Future research and programmes should continue to collect 22 
data that enables analyses of factors that influence adherence, so to increase 23 
understanding and useful guidance across the sector. 24 





This service evaluation evidences an effective PR service that leads to positive 2 
physiological and quality of life outcomes that are evidenced by MCIC’s. Basic exercise 3 
programming and assessment are feasible, led to significant improvements in 1RM 4 
strength and should be implemented in PR services to maximize patient outcomes. This 5 
may have further reaching effects upon patient adherence and continuance, which 6 
requires further study. Where time effective and economically viable approaches to PR 7 
services are key to both patient and provider, correctly administered strength training 8 
may benefit all. 9 
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Table 1. Descriptive statistics of sample by programme version 
 Programme version A Programme version B Programme version C 
 
Total 
n 76 79 78 233 
Sex 44 males; 








(years)  ± SD 
70.1 ± 8.7 72.3 ± 7.4 72.7 ± 8.2 71.7 ± 8.1 
Range: 45 – 90 
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Range: 45 – 90 


























Table 2. Mean ± SD values by location and time-point 
Measure 
 Location and time-point 
 Location A Location B  Location C Total 
 Start End Start End Start End Start End 
1RM (kg) 
Mean ± SD 
8.7 ± 3.1 
(biceps) 
10.5 ± 3.8 
 
 11.5 ± 5.7 
(quadriceps) 
17.0 ± 10.9 
 
    






    
n 47 42     
ISWT (m) 
Mean ± SD 199.8 ± 131.7 246.6 ± 127.3 
172.61 ± 98.4 
 
210.7 ± 115.1 
211.1 ± 129.6 
 
254.8 ± 139.1 196.7 ± 123.2 239.9 ± 129.3 












n 62 46 63 171 
CAT 
§ 
Mean ± SD 21.5 ± 7.6 20.1 ± 8.2 21.4 ± 7.6 
19.0 ± 7.4 
** 
17.6 ± 7.7 15.9 ± 6.5 20.2 ± 7.8 18.3 ± 7.6 
Median (IQR) 21.5 (11.0) 19.5 (12.8) 22.0 (11.3) 19.5 (11.3) 18.0 (9.0) 16.5 (8.8) 20.0 (11.0) 18.0 (11.0) 
n 68 70 68 206 
CCQ 
Mean ± SD 2.70 ± 1.21 2.50 ± 1.12 3.00 ± 1.43 2.61 ± 1.26 2.23 ± 1.00 2.08 ± 1.15 2.64 ± 1.25 2.40 ± 1.20 
Median (IQR) 2.75 (1.58) 2.50 (1.50) 2.7 (1.70) 2.50 (1.70) 2.20 (1.20) 2.10 (1.30) 2.50 (1.50) 2.20 (1.60) 
n 64 69 68 201 
HADS Anxiety 
Mean ± SD 5.90 ± 3.57 5.78 ± 3.63 6.00 ± 4.14 5.56 ± 3.79 4.10 ± 3.22 3.84 ± 3.14 5.33 ± 3.75 5.06 ± 3.62 
Median (IQR) 5.00 (5.00) 5.78 (5.00) 6.00 (6.00) 5.56 (6.25) 3.00 (5.00) 3.00 (5.00) 5.00 (5.00) 5.00 (6.00) 
n 69 70 70 209 
HADS 
Depression 




Median (IQR) 7.00 (5.00) 7.00 (6.00) 5.50 (5.25) 6.00 (6.00) 4.00 (4.00) 4.00 (5.00) 5.00 (5.00) 6.00 (6.00) 
n 69 70 70 209 
§ indicates variable was normally distributed 
Mean / Median in bold text indicates the appropriate value to assess in relation to minimal clinically important change. 















Table 3. Mean ± SD Changes in outcomes measures by COPD severity classification 
Measure  COPD Severity 
  Mild Moderate Severe Very Severe 
Δ ISWT (m) 
§ 
Mean ± SD 49.0 ± 46.5  ** 60.7 ± 67.3  ** 19.3 ± 64.1 30.0 ± 35.7 
95% CI 15.7, 82.3 34.6, 86.8 -5.1, 43.7 7.3, 52.7 
Median (IQR) 45.0 (87.5) 50.0 (80.0) 25.0 (57.5) 20.0 (50.0) 
n 10 28 29 12 
Δ CAT 
 
Mean ± SD -2.5 ± 5.6  -1.7 ± 5.5 -2.0  ± 6.1  1.9 ± 4.9 
95% CI -6.0, 1.1 -3.8, 0.5 -4.0, 0.0 -1.0, 4.7 
Median (IQR) -1.5 (12.5) -2.0 (5.5) ** 2.5 (7.0) ** 2.0 (10.0) ** 
n 13 28 37 14 
Δ CCQ 
Mean ± SD -0.01 ± 0.46 -0.17 ± 0.84 0.04 ± 1.40 -0.11 ± 0.69 
95% CI 0-0.28, 0.27 -0.50, 0.17 0.04, 0.53 -0.53, 0.31 
Median (IQR) -0.20 (0.97) -0.10 (0.90) -0.20 (0.83) 0.00 (1.50) 
n 13 26 34 13 
Δ HADS 
Anxiety 
Mean ± SD -0.64 ± 2.92 -0.82 ± 3.21 -0.38 ± 2.99 0.36 ± 1.65 
95% CI -2.33, 1.05 -2.07, 0.42 -1.38, 0.62 -0.59, 1.31 
Median (IQR) 0.00 (2.50) 0.00 (3.50) 0.00 (2.50) 1.00 (2.00) 




Mean ± SD -0.29 ± 2.61 -0.64 ± 2.26 -0.05 ± 2.77 0.43 ± 1.50 
95% CI -1.80, 1.22 1.52, 0.24 -0.98, 0.87 -0.44, 1.30 
Median (IQR) -0.50 (3.75) -1.00 (3.50) 0.00 (3.00) 0.00 (2.00) 
n 14 28 37 14 
§ indicates variable was normally distributed 




** Indicates clinically important change from start to end of programme 
 
 
 
 
 
 
 
 
 
